Aurora Cannabis Swings To Negative Cash Flow In Q1 2027
Aurora Cannabis (ACB) reported Q1 fiscal 2027 net revenue of $67.6M, down 9% YoY and 20% QoQ. Medical revenue was $64.0M, with Canadian medical down 25% YoY to $20.7M after a federal reimbursement change. Loss from continuing ops was $4.0M and free cash flow was -$5.8M. Cash fell to $149.1M.
How this was made
The 30-second read
Why it matters
The key trade signal is the shift to negative free cash flow and weaker adjusted EBITDA, with management attributing Canadian medical revenue declines to a federal reimbursement program change effective April 1.
Market read
Traders can reassess near-term risk around reimbursement-driven revenue pressure and cash burn, while monitoring whether managements sequential Q2 improvement guidance materializes.
What to watch
Gross profit increased due to biological-asset fair-value gains, so investors may need to separate accounting-driven improvements from underlying cash earnings power.
Background
Aurora Cannabis is a medical cannabis-focused operator with revenue split between Canadian and international medical markets, plus a shrinking consumer channel.
Ticker impact
Aurora Cannabis reported Q1 fiscal 2027 revenue of $67.6M, down 9% YoY, and free cash flow of -$5.8M after a federal reimbursement rate cut.
Near-term downside bias as investors weigh cash burn and reimbursement-driven revenue pressure, despite reiterated sequential improvement guidance.
The article provides multiple concrete deterioration datapoints (revenue down, adjusted EBITDA down, FCF turned negative) and links a major driver to a policy change, which typically increases earnings and cash-flow uncertainty.
Market effects
Reinforces that US/Canadian medical cannabis reimbursement policy changes can quickly pressure top-line and cash generation across the sector.
Canada-focused medical reimbursement dynamics appear to be a key swing factor for Canadian cannabis operators.
Limited direct global read-through beyond medical cannabis reimbursement and channel normalization themes.
Counterpoint
International medical revenue rose and management reiterated sequential improvement, which could offset the Canadian reimbursement drag if trends stabilize.
Key entities
- companyAurora Cannabis
Reported Q1 fiscal 2027 results showing revenue decline, lower adjusted EBITDA, and negative free cash flow tied to reimbursement rate reductions.
